The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia

Molecular Biotechnology

Volumn 36, Issue 2, 2007, Pages 81-89

  Griffiths, Stephen D ^a   Burthem, John ^b   Unwin, Richard D ^a   Holyoake, Tessa L ^c   Melo, Junia V ^d   Lucas, Guy S ^b   Whetton, Anthony D ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Chronic myeloid leukemia; Imatinib; iTRAQ; Mass spectrometry

Indexed keywords

CELLS; DISEASES; ENZYME ACTIVITY; MASS SPECTROMETRY;

CHRONIC MYELOID LEUKEMIA; IMATINIB;

PEPTIDES;

CHIMERIC PROTEIN; DEAD BOX PROTEIN; HEAT SHOCK PROTEIN; IMATINIB; PEROXIREDOXIN; ANTINEOPLASTIC AGENT; DDX3X PROTEIN, HUMAN; HEAT SHOCK PROTEIN 110; HSPH1 PROTEIN, HUMAN; PEPTIDE; PEROXIDASE; PEROXIREDOXIN III; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEOME; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PEPTIDE ANALYSIS; PROTEOMICS; QUANTITATIVE ANALYSIS; APOPTOSIS; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; HEMATOPOIETIC STEM CELL; METABOLISM; METHODOLOGY; TANDEM MASS SPECTROMETRY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATOGRAPHY, LIQUID; DEAD-BOX RNA HELICASES; HEMATOPOIETIC STEM CELLS; HSP110 HEAT-SHOCK PROTEINS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PEPTIDES; PEROXIDASES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEOME; PROTEOMICS; PYRIMIDINES; TANDEM MASS SPECTROMETRY; TUMOR CELLS, CULTURED;

EID: 35848931437     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12033-007-0005-5     Document Type: Article

References (49)

1. Sattler, M., & Griffin, J. D. (2001). Mechanisms of transformation by the BCR/ABL oncogene. International journal of hematology, 73, 278-291.
2. Melo, J. V. (1997). BCR/ABL gene variants. Baillieres Clinical Haematology, 10, 203-222.
3. Takahashi, N., Miura, I., Saitah, K., & Miura, A. B. (1998). Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukaemia in the chronic phase as shown by the combination of fluorescent-activated cell sorting and fluorescent in situ hybridisation. Blood, 92, 4758-4763.
4. Haferlach, T., Winkermann, M., Nickenig, C., Meeder, M., Ramm-Petersen, L., Schoch, R., Nickelsen, M., Weber-Matthiesen, K., Schlegelberger, B., Schoch, C., Gassmann, W., & Loffler, H. (1997). Which compartments are involved in Philadelphia-chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May-Grunwald-Giemsa staining and fluorescence in situ hybridization techniques. British journal of haematology, 97, 99-106.
5. Ogawa, M., Fried, J., Sakai, Y., Strife, A., & Clarkson, B. D. (1970). Studies of cellular proliferation in human leukaemia. VI. The proliferative activity, generation time, and emergence time of neutrophilic granulocytes in chronic granulocytic leukaemia. Cancer, 25, 1031-1049.
6. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J. & Lydon, N. B. (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature medicine, 2, 561-566.
7. Heinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000). Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood, 96, 925-932
8. Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000). Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. The Journal of pharmacology and experimental therapeutics, 295, 139-145.
9. O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., Lechner, K., Nielsen, J. L., Rousselot, P., Reiffers, J., Saglio, G., Shepherd, J., Simonsson, B., Gratwohl, A., Goldman, J. M., Kantarjian, H., Taylor, K., Verhoef, G., Bolton, A. E., Capdeville, R., & Druker, B. J. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. The New England journal of medicine , 348, 994-1004.
10. Oehler, V. G., Gooley, T., Snyder, D. S., Johnston, L., Lin A., Cummings, C. C., Chu, S., Bhatia, R., Forman, S. J., Negrin, R. S., Appelbaum, F. R., & Radich, J. P. (2007). The effects of imatinib mesylate treatment before allogeneic transplant for chronic myeloid leukaemia. Blood, 109, 1782-1789.
11. Hughes, T. P., Kaeda, J., Branford, S., Rudzski, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., & Radich, J. P. (2003). Frequency of major molecular response to imatinib or interferon-alpha plus cytarabine in newly diagnosed chronic myeloid leukaemia. The New England journal of medicine, 349, 1423-1432.
12. Lin, F., Drummond, M., O'Brien, S., Cervantes, F., Goldman, J. & Kaeda, J. (2003). Molecular monitoring in chronic myloid leukemis patients who achieve complete cytogenetic remission on imatinib. Blood, 102, 1143.
13. Bhatia, R., Holtz, M., Niu, N., Gray, R., Sneyder, D. S., Sawers, C. L., Arber, D. A., Slovak, M. L., & Forman, S. J. (2003). Persistence of malignant hematopoietic progenitors in chronic myelogenous leukaemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood, 101, 4701-4707.
14. O'Brien, S. G., & Rule, S. A. (2002). Position paper on imatinib mesylate in chronic myeloid leukaemia. British journal of haematology, 119, 268-272.
15. Pandey, A., & Mann, M. (2000). Proteomics to study genes and genomes. Nature, 405, 837-846.
16. Rappsilber, J., & Mann, M. (2002). What does it mean to identify a protein in proteomics? Trends in biochemical sciences, 27, 74-78.
17. Wang, J. C. Y., & Dick, J. E. (2005). Cancer stem cells: lessons from leukaemia. Trends in cell biology , 15, 494-501.
18. Marley, S. B. & Gordon, M. Y. (2005). Chronic myeloid leukaemia: stem cell derived but progenitor cell driven. Clinical Science, 109, 13-25.
19. Zou L., Wu, Y., Pei, L., Zhong, D., Gen, M., Zhao, T., Wu, J., Ni, B., Mou, Z., Han, J., Chen, Y., & Zhi, Y. (2005). Identification of leukaemia-associated antigens in chronic myeloid leukaemia by proteomic analysis. Leukemia research, 29, 1387-1391.
20. Hegedus, C. M., Gunn, L., Skibola, C. F., Zhang, L., Shiao, R., Fu, S., Dalmasso E. A., Metayer, C., Dahl, G. V., Buffler, P. A., & Smith, M. T. (2005). Proteomic analysis of childhood leukaemia. Leukemia, 19, 1713-1718.
21. Abramovitz, M., & Leyland-Jones, B. R. (2006). A systems approach to clinical oncology: Focus on breast cancer. Proteome science, 4:5, 1-15.
22. Unwin, R. D., Smith, D. L., Blinco, D., Wilson, C. L., Miller, C. J., Evans, C. A., Jaworska, E., Baldwin, S. A., Barnes, K., Pierce, A., Spooncer, E., & Whetton, A. D. (2006). Quantitative proteomics reveals post-translational control as a regulatory factor in primary hematopoietic stem cells. Blood, 107, 4687-4694.
23. Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B., Parker, K., Hattan, S., Khainovski, N., Pillai, S., Dey, S., Daniels, S., Purkayastha, S., Juhasz, P., Martin, S., Bartlet-Jones, M., He, F., Jacobson, A., & Pappin, D. J. (2004). Multiplexed protein quantification in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Molecular & cellular proteomics, 3, 1154-1169.
24. Graham, S. M., Jorgenson, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., & Holyoake, T. L. (2002). Primitive, quiescent Philadelphia positive stem cells from patients with chronic myeloid leukaemia are insensitive to STI571 in vitro. Blood, 99, 319-325.
25. Unwin, R. D., Pierce, A., Watson, R. B., Sternberg, D. W., & Whetton, A. D. (2005). Quantitative proteomic analysis using isobaric protein tags enables rapid comparisons of changes in transcript and protein levels in transformed cells. Molecular & cellular proteomics, 4, 924-935.
26. Hancock, W. S., Wu, S. -L., & Shieh, P. (2002). The challenges of developing a sound proteomics strategy. Proteomics, 2, 352-359.
27. Copland, M., Hamilton, A., Elrick, L. J., Baird, J. W., Allan, E. K., Jordanides, N., Barrow, M., Mountford, J. C., & Holyoake, T. L. (2006). Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood, 107, 4532-4539.
28. Gambascorti-Passerini, C., le Courte, P., Mologni, L., Fanelli, M., Bertazzoli, C., Marchesi, E., Di Nichola, M., Biondi, A., Corneo, G. M., Belotti, D., Pogliani, E., & Lydon, N. B. (1997). Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood cells, molecules & diseases, 23, 380-394.
29. Kramer, A., Loffler, H., Bergmann, J., Hochhaus, A., & Hehlmann, R. (2001). proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukaemia. Leukaemia, 15, 62-68.
30. Holtz, M. S., Slovak, M. L., Zhang, F., Sawers, C. L., Forman, S. J., & Bhatia, R. (2002). Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukaemia through reversal of abnormally increased roliferation. Blood, 99, 3792-3800.
31. Vigneri, P., & Wang, J. Y. (2001). Introduction of apoptosis in chronic myelogenous leukaemia cells through nuclear entrapment of BCR/ABL tyrosine kinase. Nature medicine, 7, 228-234.
32. Fang, G., Kim, C. N., Perkins, C. L., Ramadevi, N., Winton, E., Wittmann, S., & Bhalla, K. N. (2000). CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl positive human leukaemia cells to apoptosis due to antileukemic drugs. Blood, 96, 2246-2253.
33. Lilley, K. S. & Friedman, D. B. (2004). All about DIGE: Quantification technology for differential-display 2D-gel proteomics. Expert review of proteomics, 1, 401-409.
34. DeSouza, L., Diehl, G., Rodrigues, M. J., Guo, J., Romaschin, A. D., Colgan, T. J., & Siu, K. W. (2005). Search for cancer markers from endometrial tissues using differentially labelled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. Journal of proteome research, 4, 377-386.
35. Listgarten, J., & Emili, A. (2005). Statistical and computational methods for comparative proteomic profiling using liquid chromatography-tandem mass spectrometry. Molecular & cellular proteomics, 4, 419-434.
36. Jongen-Lavrencic, M., Salesse, S., Delwel, R., & Verfaillie, C. M. (2005). BCR/ABL-mediated down regulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CC19 and CCL21 in primary BCR/ABL-positive cells. Leukemia, 3, 373-380.
37. Villuendas, R., Steegmann, J. L., Pollan, M., Tracey, L., Granda, A., Fernandez-Ruiz, E., Lombardia, L., Villalon, L., Odriozola, J., & Piris, M.A. (2006). Identification of genes involved in imatinib resistance in CML: A gene expression profiling approach. Leukemia, 20, 1047-1054.
38. Ren, R. (2005). Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nature reviews. Cancer, 3, 172-183.
39. Rocak, S., & Linder, P. (2004). DEAD-box proteins: the driving forces behind RNA metabolism. Nature reviews. Molecular cell biology, 5, 232-239.
40. Zhou, Z., Licklider, L. J., Gygi, S.P., & Reed, R. (2002). Comprehensive proteomic analysis of the human spliceosome. Nature, 419, 182-185.
41. waf1/cip1promoter, is a candidate tumour suppressor. Cancer research, 66, 6579-6588.
42. Hatayama, T., Yamagishi, N., Minobe, E., & Sakai, K. (2001). Role of hsp105 in protection against stress-induced apoptosis in neuronal PC12 Cells. Biochemical and biophysical research communications, 288, 528-534.
43. Ray, S., Lu, Y., Kaufmann, S. H., Gustafson, W. C., Karp, J. E., Boldogh, I., Fields, A. P., & Brasier, A. R. (2004). Genomic mechanisms of p210BCR-ABL signalling: Induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis. The Journal of biological chemistry, 279, 35604-35615.
44. Guo, F., Sigua, C., Bali, P., George, P., Fiskus, W., Scuto, A., Annavarapu, S., Mouttaki, A., Sondarva, G., Wei, S., Wu, J., Djeu, J., & Bhalla, K. (2005). Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukaemia cells. Blood, 105, 1246-1255.
45. Chang, T. -S., Cho, C. -S., Park, S., Yu, S., Kang, S. W., & Rhee, G. (2004). Periredoxin III, a mitochondrion-specific peroxidase, regulates apoptotic signalling by mitochondria. The Journal of biological chemistry, 279, 41975-41984.
46. Jackson, A. L., & Loeb, L. A. (2001). The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutation research, 477, 7-21.
47. Sattler, M., Verma, S., Shrikhande, G., Byrne, C. H., Pride, Y. B., Winkler, T., Greenfield, E. A., Salgia, R., & Griffin, J. D. (2000). The Bcr-Abl tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. The Journal of biological chemistry, 275, 24273-24278.
48. Kim, J. H., Chu, S. C., Gramlich, J. L., Pride, Y. B., Babendreier, E., Chauhan, D., Salgia, R., Podar, K., Griffin, J. D., & Sattler, M. (2005). Activation of the PI3 K/mTOR pathway by BCR-ABL contributes to increased production reactive oxygen species. Blood, 105, 1717-1723.
49. Koptyra, M., Falinski, R., Nowicki, M. O., Stoklosa, T., Majsterek, I., Nieborowska-Skorska, M., Blasiak, J., & Skorski, T. (2006). BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood, 108, 319-327.